SISLOT valley-dose IGF-1R-AKT-IL-33 release as chemotactic beacon for gut-derived KLRG1+ ILC2s

Pancreatic cancer is one of the deadliest cancers partly because of its fortress-like architecture: a thick wall of scar-like tissue surrounds the tumor and physically blocks immune cells from getting in. Meanwhile, a cutting-edge radiation technique called spatially fractionated radiation therapy (SFRT) deliberately delivers radiation in a striped pattern — alternating high-dose 'peaks' and lower-dose 'valleys' across a tumor — rather than blasting everything uniformly. Researchers have focused mostly on the high-dose peaks, but this hypothesis asks: what is the low-dose valley doing to the immune system? The proposal is that those valley zones, receiving a relatively gentle dose of radiation (roughly half a gray to two gray), cause subtle but important stress in the tumor's structural support cells — the fibroblasts. This stress activates a specific molecular chain reaction (IGF-1R → AKT → IL-33) that ends with the release of a signaling protein called IL-33. IL-33 acts like a chemical beacon, forming a concentration gradient that attracts a rare type of immune cell called ILC2s — which, intriguingly, appear to travel all the way from the gut via the bloodstream. When these gut-derived ILC2s pass through blood vessels near the valley zones and sense the IL-33 signal, they exit the bloodstream and set up camp there. Once concentrated, these cells kick off the construction of 'tertiary lymphoid structures' — essentially pop-up lymph nodes inside the tumor that can coordinate a much more powerful immune attack. Because the radiation is delivered in a helical pattern with a fixed spacing of about 7.5 millimeters, the hypothesis makes a testable, almost geometric prediction: the mini lymph nodes that form should be spaced roughly 7.5 millimeters apart in surgically removed tissue. This is a bold, mechanistically detailed idea sitting at the intersection of radiation physics, immunology, and cancer biology. It pulls together findings from very different fields — radiation bystander effects, gut immune cell trafficking, and the emerging science of tertiary lymphoid structures — and stitches them into a single coherent story. The confidence is appropriately modest because several links in the chain remain unproven in pancreatic cancer specifically, but the hypothesis is falsifiable in ways that make it genuinely worth testing.

This is an AI-generated summary. Read the full mechanism below for technical detail.